By a News Reporter-Staff News Editor at Computer Weekly News -- Investigators publish new report on Drugs and Therapies - Antihypertensives. According to news reporting from Varese, Italy, by VerticalNews journalists, research stated, “To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 double-blind, randomized, ambulatory BP monitoring (ABPM) studies. ABPMs were performed before and after 6-12 weeks of treatment with placebo (n=119), active control monotherapy [n=1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)] olmesartan monotherapy (n=1410), active control dual combination [n=79, DCCB+thiazide diuretic (TD)], olmesartan dual combination (n=637, DCCB or TD), and triple combination therapy (n=102, DCCB+TD). 24-h BPV was calculated as unweighted or weighted SD of the mean BP, and average real variability.”
The news correspondents obtained a quote from the research from Clinical and Research Unit, “BP control was assessed by smoothness index and treatment-on-variability index. The greatest effect on 24-h systolic BPV/diastolic BPV was observed under olmesartan triple [-2.6/-1.9; -1.9/-1.3; -1.4/-1.3mmHg] and active control dual combination [-1.8/-1.4; -1.9/-1.5; -1.2/-1.1mmHg]. Smoothness indexes and treatment-on-variability indexes were significantly (P=0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00). They were also greater in patients receiving high-dose olmesartan monotherapy or high-dose olmesartan dual combination than in the corresponding low-dose group.”
According to the news reporters, the research concluded: “Olmesartan plus a DCCB and/or a TD produces a larger, more sustained, and smoother BP reduction than placebo and monotherapies, a desirable feature for a more effective prevention of the cardiovascular consequences of uncontrolled hypertension.”
For more information on this research see: Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. Journal of Hypertension , 2018;36(4):720-733. Journal of Hypertension can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Journal of Hypertension - http://journals.lww.com/jhypertension/pages/default.aspx)
Our news journalists report that additional information may be obtained by contacting S. Omboni, Italian Inst Telemed, Clin Res Unit, Varese, Italy. Additional authors for this research include K. Kario, G. Bakris and G. Parati.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-04-25), Reports on Antihypertensives Findings from Clinical and Research Unit Provide New Insights (Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies ...), Computer Weekly News, 665, ISSN: 1944-1606, BUTTER® ID: 015549751
From the newsletter Computer Weekly News.
https://www.newsrx.com/Butter/#!Search:a=15549751
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.